The digital mental health provider organization Cerebral has changed its prescribing practices for adults diagnosed with attention deficit/hyperactivity disorder (ADHD). As of May 9, 2022, no new consumers will be prescribed stimulants (Adderall or Ritalin) as treatment for ADHD, while existing consumers with ADHD will be permitted to continue receiving prescriptions for stimulants. This change in policy was announced days before the company announced that it had received a grand jury subpoena from the U.S. Attorney’s Office for the Eastern District of New York investigating its prescribing practices for possible violations of the federal Controlled Substances Act . . .